Website / Social Media update

RNS Number : 8073Y

MGC Pharmaceuticals Limited

08 September 2022

 

 MGC Pharmaceuticals Ltd.

Website / Social Media update

08 September 2022

ASX, LSE: MXC

As a result of MGC Pharmaceuticals ( 'MGC Pharma' or 'the Company') deepening presence within the pharmaceutical sector, the Company has temporarily deactivated their website and social media profiles to complete required upgrades and re-branding. This will facilitate them to unveil their global vision across all platforms simultaneously and without ambiguity

Once the upgrades are completed, this will ensure that the Company is fully compliant with the Therapeutic Goods Administration (TGA), European Medicines Agency (EMA) and Food and Drugs Administration (FDA) regulations.

The Company will make a further announcement when the website and social media pages are live again.

--Ends--

Authorised for release by the Chairman, for further information please contact:

MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd David Lim Company Secretary [phone] [e-mail]
UK Broker - Turner Pope Andy Thacker [phone] [e-mail]	UK PR Advisors - Tavistock Charles Vivian / Tim Pearson [phone] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America, and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far, therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil, and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

 

END

 

 

MSCEAFNPELKAEFA